Relief as new oral drug for type two diabetes launched

Physician Dr Rosemary Wanjiru, Dr Eva Njenga, an endocrinologist, and DrMichael Mark of Boehringer Ingelheim at the symposium in Nairobi.
Physician Dr Rosemary Wanjiru, Dr Eva Njenga, an endocrinologist, and DrMichael Mark of Boehringer Ingelheim at the symposium in Nairobi.

​​​​Patients of type two diabetes got some relief yesterday after a new oral drug to manage the disease was launched.

The drug, called Trajenta, improves glycemic control, diet and exercise in adults.

Its introduction was announced during a scientific conference in Nairobi by Boehringer Ingelheim, one of the world’s leading pharmaceutical companies.

Ayman Eissa, head of Boehringer Ingelheim, said lack of awareness and an increasing prevalence of the disease had become obstacles to reducing the rise of diabetes.

The drug is available only as prescription medicine upon recommendation by a doctor. It is simple. effective and safe, the experts said.

Ayman

said, “Lack of awareness and an increasing prevalence of type 2 diabetes are critical obstacles to overcoming the rise of diabetes in Kenya. At Boehringer, we believe that Kenya and the wider

African continent has an opportunity to reduce the burden of the disease by working towardsdeveloping comprehensive protocols towards managing type 2 diabetes. That is why our work in Kenya and across

Africa

focuses on facilitating quality care while also adding more value to overall health systems.”